Method for detecting anti-tuberculosis drug in serum by ultra-high performance liquid chromatography-tandem mass spectrometry technology

An ultra-high performance liquid chromatography and tandem mass spectrometry technology, which is applied in the field of ultra-high performance liquid chromatography tandem mass spectrometry detection of anti-tuberculosis drugs in serum, can solve the problems of unreachable drug concentration, high cost, cumbersome detection process, etc., and achieve simple Rapid detection method, accurate pretreatment process, high sensitivity effect

Inactive Publication Date: 2020-10-13
南京品生医学检验实验室有限公司
View PDF2 Cites 3 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

It is easy to cause the drug concentration in the body to be too low, so that the therapeutic drug concentration cannot be reached, or the drug concentration in the body is too high to cause toxic reactions. sex is more important
[0004] At present, the method for detecting the concentration of anti-tuberculosis drugs in the body is mainly ultra-high performance liquid chromatography-tandem mass spectrometry. Most of the reports in the literature are for the detection of 1-3 kinds of drugs at one time, and there are

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Method for detecting anti-tuberculosis drug in serum by ultra-high performance liquid chromatography-tandem mass spectrometry technology
  • Method for detecting anti-tuberculosis drug in serum by ultra-high performance liquid chromatography-tandem mass spectrometry technology
  • Method for detecting anti-tuberculosis drug in serum by ultra-high performance liquid chromatography-tandem mass spectrometry technology

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0047] 1. Materials

[0048] (1) The samples of the methodological research experiment came from the serum samples collected from the outpatient clinic of Nanjing Drum Tower Hospital in August 2019.

[0049] (2) Instruments: Xevo TQ-S triple quadrupole mass spectrometer (Waters Corporation); UPLC I-Class ultra-high performance liquid chromatography system (with automatic sampler, Waters Corporation); SCILOGEX D2012 high-speed desktop centrifuge (USA) ; ultrapure water instrument (ELGA LabWater, UK); multi-tube vortex mixer (Vortex genie2, US); adjustable pipette (Eppendorf 0.5-10 μL, 10-100 μL, 100-1000 μL); glassware, Graduated cylinder, etc.

[0050] (3) Reagent consumables: MS grade methanol (Fisher, USA); HPLC grade methanol (Honeywell, USA); MS grade acetonitrile (Fisher, USA); HPLC grade acetonitrile (Honeywell, USA); MS grade formic acid (Fisher, USA) MS grade ammonium formate (Sigma, USA) chromatographic column: Phenomenex Kintex C18 (2.1×100mm, 2.6 μm) (Phenomenex, ...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention discloses a method for detecting an anti-tuberculosis drug in serum by an ultra-high performance liquid chromatography-tandem mass spectrometry technology. The antitubercular drug comprises cycloserine (CYS), pyrazinamide (PZN), isoniazid (INZ), p-aminosalicylic acid (P-ASA), ethiisonicotinamide (ETN), ethambutol (ETB), clofazimine (CFM), bedaquiline (BDQ), rifampicin (RFP), rifbutine (RFB) and rifapentine (RFT). The method includes: detecting the content of the antituberculosis drug in the pretreated serum by adopting an ultra-high performance liquid chromatography-tandem mass spectrometry method, performing quantifying by utilizing a mass spectrometry isotope internal standard method, establishing a calibration curve by taking the concentration ratio of the standard substance to the internal standard substance as an X axis and the peak area ratio of the standard substance to the internal standard substance as a Y axis, and calculating the concentration of the target drug in the serum; the method is high in sensitivity, strong in specificity and simple in pretreatment process, separation and detection of the anti-tuberculosis drugs in serum are completed within 5 min, and a simple and rapid detection method is provided for clinical concentration monitoring of the anti-tuberculosis drugs.

Description

technical field [0001] The invention belongs to the technical field of analysis and detection, and more specifically relates to a method for detecting anti-tuberculosis drugs in serum by ultra-high performance liquid chromatography tandem mass spectrometry. Background technique [0002] Tuberculosis is an infectious disease caused by patients infected with Mycobacterium tuberculosis. So far, tuberculosis is still the infectious disease that causes the highest human mortality rate except AIDS. Anti-tuberculosis drugs are mainly divided into four categories: first-line anti-tuberculosis drugs, second-line anti-tuberculosis drugs, new anti-tuberculosis drugs, and compound drugs. [0003] In this patent, the first-line anti-tuberculosis drugs involved mainly include rifampicin (Rifamicin, RMP), isoniazid (Isoniazid, INH), pyrazinamide (Pvrazinamide, PZA) and ethambutol (Ethambutol, EMB) ; First-line anti-tuberculosis drugs are still the first choice for the treatment of tubercu...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): G01N30/02G01N30/06G01N30/72G01N30/86
CPCG01N30/02G01N30/06G01N30/7266G01N30/8679G01N2030/045G01N2030/067
Inventor 成晓亮李美娟
Owner 南京品生医学检验实验室有限公司
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products